Potential new clinical therapies for Chagas disease

被引:36
作者
Bustamante, Juan M. [1 ]
Tarleton, Rick L. [1 ,2 ]
机构
[1] Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA
[2] Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA
关键词
Chagas disease; clinical trials; drug discovery; drug treatment; Trypanosoma cruzi; CYSTEINE PROTEASE INHIBITORS; TRYPANOSOMA-CRUZI INFECTION; IN-VIVO ACTIVITIES; CHRONIC PHASE; MURINE MODEL; ETIOLOGIC TREATMENT; CARDIAC DAMAGE; BENZNIDAZOLE; CHEMOTHERAPY; ALLOPURINOL;
D O I
10.1586/17512433.2014.909282
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chagas disease is the highest impact parasitic disease in the Americas but often goes untreated due to the shortcomings of currently available therapeutics. Thus there is an urgent need for new treatment options and growing interest in drug development for the infection. This review summarizes some of the recent advances and failures in this realm, with particular emphasis on recently published studies and unpublished results presented at a recent Chagas Drug Discovery Consortium meeting.
引用
收藏
页码:317 / 325
页数:9
相关论文
共 100 条
  • [1] [Anonymous], 2001, Antimalarial drug combination therapy. Report of a WHO Technical Consultation. WHO/CDS/RBM/2001.35
  • [2] Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up
    Apt, W
    Arribada, A
    Zulantay, I
    Sanchez, G
    Vargas, SL
    Rodriguez, J
    [J]. ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 2003, 97 (01): : 23 - 29
  • [3] A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease
    Araújo, MSS
    Martins-Filho, OA
    Pereira, MES
    Brener, Z
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (06) : 819 - 824
  • [4] Design, Synthesis, Calorimetry, and Crystallographic Analysis of 2-Alkylaminoethyl-1,1-bisphosphonates as Inhibitors of Trypanosoma cruzi Farnesyl Diphosphate Synthase
    Aripirala, Srinivas
    Szajnman, Sergio H.
    Jakoncic, Jean
    Rodriguez, Juan B.
    Docampo, Roberto
    Gabelli, Sandra B.
    Mario Amzel, L.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (14) : 6445 - 6454
  • [5] The Trypanosoma cruzi proteome
    Atwood, JA
    Weatherly, DB
    Minning, TA
    Bundy, B
    Cavola, C
    Opperdoes, FR
    Orlando, R
    Tarleton, RL
    [J]. SCIENCE, 2005, 309 (5733) : 473 - 476
  • [6] Fexinidazole: A Potential New Drug Candidate for Chagas Disease
    Bahia, Maria Terezinha
    de Andrade, Isabel Mayer
    Fontes Martins, Tassiane Assiria
    da Silva do Nascimento, Alvaro Fernando
    Diniz, Livia de Figueiredo
    Caldas, Ivo Santana
    Talvani, Andre
    Trunz, Bernadette Bourdin
    Torreele, Els
    Ribeiro, Isabela
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2012, 6 (11):
  • [7] Therapeutic potential of boron-containing compounds
    Baker, Stephen J.
    Ding, Charles Z.
    Akama, Tsutomu
    Zhang, Yong-Kang
    Hernandez, Vincent
    Xia, Yi
    [J]. FUTURE MEDICINAL CHEMISTRY, 2009, 1 (07) : 1275 - 1288
  • [8] A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi
    Barr, SC
    Warner, KL
    Kornreic, BG
    Piscitelli, J
    Wolfe, A
    Benet, L
    McKerrow, JH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) : 5160 - 5161
  • [9] Batista Dda G, 2011, PLOS ONE, V6
  • [10] Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
    Bergstrom, JD
    Bostedor, RG
    Masarachia, PJ
    Reszka, AA
    Rodan, G
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 373 (01) : 231 - 241